Evidence map›Paper›PMID 41410776›Full record

ArticleCancer immunology, immunotherapy : CII2025

Combined CD25-targeted near infrared photoimmunotherapy (NIR-PIT) and intratumor IL-15 enhance the effectiveness of anti-PD-1 immunotherapy.

Makoto Kano, Aki Furusawa, Hiroshi Fukushima, Seiichiro Takao, Shuhei Okuyama, Hiroshi Yamamoto, Motofumi Suzuki, Miyu Kano, Ko Kitamura, Peter L Choyke and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Makoto KanoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room B3B47, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0009-0004-7659-1238
Aki FurusawaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room B3B47, Bethesda, MD, 20892, USA.
Hiroshi FukushimaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room B3B47, Bethesda, MD, 20892, USA.
Seiichiro TakaoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room B3B47, Bethesda, MD, 20892, USA.
Shuhei OkuyamaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room B3B47, Bethesda, MD, 20892, USA.
Hiroshi YamamotoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room B3B47, Bethesda, MD, 20892, USA.
Motofumi SuzukiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room B3B47, Bethesda, MD, 20892, USA.
Miyu KanoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room B3B47, Bethesda, MD, 20892, USA.
Ko KitamuraMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room B3B47, Bethesda, MD, 20892, USA.
Peter L ChoykeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room B3B47, Bethesda, MD, 20892, USA.
Hisataka KobayashiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room B3B47, Bethesda, MD, 20892, USA. kobayash@mail.nih.gov.ORCID http://orcid.org/0000-0003-1019-4112

Funding

Cancer-cell specific therapy: photo-immunotherapyZIABC011513 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$15.5M
Intramural NIH HHS ZIA BC011513NIH HHS ZIA BC 011513
6 · The paper itself

Abstract

Immunotherapies aimed at enhancing anti-cancer immunity are now in wide clinical use. For instance, anti-programmed cell death protein 1 (PD-1) monoclonal antibody (mAb) therapy has demonstrated clinical efficacy in many tumor types, but overall, only a minority of patients respond. Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that selectively destroys targeted cells. CD25-targeted NIR-PIT is a strategy that selectively depletes regulatory T cells in the tumor microenvironment, thereby enhancing the T-cell response of PD-1 mAbs. Cytokines, such as interleukin-15 (IL-15), can also modulate immune response by further activating CD8

Indexed as

Antibodies, MonoclonalImmune Checkpoint InhibitorsImmunotherapyInterleukin-15Interleukin-2 Receptor alpha SubunitPhototherapyProgrammed Cell Death 1 ReceptorAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansInfrared RaysMiceMice, Inbred C57BLT-Lymphocytes, RegulatoryAntibodies, MonoclonalImmune Checkpoint InhibitorsInterleukin-15Interleukin-2 Receptor alpha SubunitPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorAnti-PD-1 monoclonal antibodyCD8/regulatory T cell ratioHyperprogressionInterleukin-15Near-infrared photoimmunotherapy

Identifiers

PMID41410776
PMCPMC12715065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.